Scarica l'app Stockscreener
0.3163
4.67%
0.0141
Dopo l'orario di chiusura:
.31
-0.0063
-1.99%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché ADIL Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.3022
Aprire:
$0.2843
Volume 24 ore:
13.45M
Relative Volume:
13.89
Capitalizzazione di mercato:
$5.18M
Reddito:
-
Utile/perdita netta:
$-6.07M
Rapporto P/E:
-0.0547
EPS:
-5.78
Flusso di cassa netto:
$-7.34M
1 W Prestazione:
+37.94%
1M Prestazione:
-53.82%
6M Prestazione:
-68.68%
1 anno Prestazione:
-70.98%
Intervallo 1D:
$0.2715
$0.3997
Intervallo di 1 settimana:
$0.2311
$0.532
Portata 52W:
$0.22
$3.00
Adial Pharmaceuticals Inc Stock (ADIL) Company Profile
Nome
Adial Pharmaceuticals Inc
Settore
Industria
Telefono
434-422-9800
Indirizzo
1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA
Confronta ADIL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ADIL
Adial Pharmaceuticals Inc
|
0.3163 | 5.18M | 0 | -6.07M | -7.34M | -5.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Adial Pharmaceuticals Inc Stock (ADIL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-14 | Iniziato | Rodman & Renshaw | Buy |
| 2018-10-30 | Iniziato | Maxim Group | Buy |
| 2018-10-11 | Iniziato | Dawson James | Buy |
Adial Pharmaceuticals Inc Borsa (ADIL) Ultime notizie
Adial Pharmaceuticals Announces Pricing of $3.6 Million Public Offering - GlobeNewswire
Adial Pharmaceuticals (ADIL) Announces Public Offering to Raise $3.6M - GuruFocus
Adial Pharmaceuticals prices $3.6 million public offering - Investing.com
Adial Pharmaceuticals (ADIL) Sets Pricing for Stock and Warrants Offering | ADIL Stock News - GuruFocus
Adial Pharmaceuticals Announces Pricing of $3.6 Million Public Offering | ADIL Stock News - GuruFocus
Adial Pharmaceuticals prices $3.6 million public offering By Investing.com - Investing.com Nigeria
Adial Pharmaceuticals Secures $3.6M Financing: New Shares at $0.32 Plus Warrant Package - Stock Titan
Adial Pharmaceuticals Announces New Annual Meeting Date By Investing.com - Investing.com Nigeria
Adial Pharmaceuticals Announces New Annual Meeting Date - Investing.com
Adial Pharmaceuticals Reschedules 2025 Annual Meeting Date - TipRanks
Adial Pharmaceuticals Inc (ADIL) Stock: From Low to High in 52 Weeks - investchronicle.com
Adial Pharmaceuticals (ADIL) Advances Toward Phase 3 with FDA Meeting Preparation | ADIL Stock News - GuruFocus
Adial Pharmaceuticals Submits Briefing Package to Guide Upcoming FDA Meeting - GlobeNewswire
Market Update: Adial Pharmaceuticals Inc (ADIL) Sees Negative Movement, Closing at 0.35 - DWinneX
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Down 63.0% in May - Defense World
ADIL Stock on the Rise: A Promising Investment - investchronicle.com
Adial Pharmaceuticals advances Phase 3 trial design for alcohol disorder drug By Investing.com - Investing.com South Africa
EXCLUSIVE: Intelligent Bio Solutions Expands US Forensic Market Presence, Seeks FDA Clearance For Fingerprint Drug Testing - AOL.com
Adial Pharmaceuticals advances Phase 3 trial design for alcohol disorder drug - Investing.com
Adial Pharmaceuticals (ADIL) Advances Phase 3 Trial Plans for AD04 | ADIL Stock News - GuruFocus
Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04 - The Manila Times
Revolutionary AI-Powered Phase 3 Trial: How Adial Plans to Transform Alcohol Addiction Treatment - Stock Titan
EXCLUSIVE: Adial Pharmaceuticals Lead Candidate For Alcohol Use Disorder Advances Toward Phase 3 Trial - Yahoo Finance
ADIL: A.G.P./Alliance Global Partners Appointed as Sole Placemen - GuruFocus
ADIL: A.G.P./Alliance Global Partners Appointed as Sole Placement Agent | ADIL Stock News - GuruFocus
Adial Pharmaceuticals (ADIL) Files to Sell Over 6 Million Shares - GuruFocus
Adial Pharmaceuticals Faces Nasdaq Non-Compliance Notice - TipRanks
Adial Pharmaceuticals (ADIL) Files to Sell Over 6 Million Shares | ADIL Stock News - GuruFocus
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update - Defense World
ADIL Q2 EPS Increased by Brookline Capital Management - Defense World
Adial Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Adial Pharmaceuticals sets new proposal deadline By Investing.com - Investing.com Nigeria
Adial Pharmaceuticals sets new proposal deadline - Investing.com
Adial Pharmaceuticals (ADIL) Reports Q1 2025 Results | ADIL Stoc - GuruFocus
Adial Pharmaceuticals Reports First Quarter 2025 Financial Resul - GuruFocus
Adial Pharmaceuticals (ADIL) Reports Q1 2025 Results | ADIL Stock News - GuruFocus
Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update | ADIL Stock News - GuruFocus
Adial Pharmaceuticals Q1 2025 Financial Results and Business Update - TradingView
Adial Pharmaceuticals Advances AUD Drug to Phase 3, Cuts Losses by 66% in Q1 2025 Earnings - Stock Titan
ADIAL PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Adial Pharmaceuticals (ADIL) Receives Milestone Payment for Asth - GuruFocus
Adial Pharmaceuticals (ADIL) Receives Milestone Payment for Asthma Drug Development | ADIL Stock News - GuruFocus
Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study - The Manila Times
Adial Pharmaceuticals (ADIL) Projected to Post Quarterly Earnings on Tuesday - Defense World
FDA to Review Adial’s Phase 3 Trial Plan for AUD Treatment - Investing.com Nigeria
FDA Has Granted Request for End of Phase 2 Meeting to Discuss Alcohol Use Disorder Treatment, AD04 - Psychiatric Times
FDA to Review Adial’s Phase 3 Trial Plan for AUD Treatment By Investing.com - Investing.com South Africa
Adial Pharmaceuticals Granted End Of Phase 2 Meeting From FDA - marketscreener.com
EXCLUSIVE: Adial Pharmaceuticals Secures FDA End of Phase 2 Meeting Request To Discuss Upcoming Clinical Development Plan For Lead Program - AOL.com
Adial Pharmaceuticals (ADIL) Receives FDA Green Light for Phase 3 Meeting | ADIL Stock News - GuruFocus
Adial Pharmaceuticals Inc Azioni (ADIL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.39%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):